For how we live.
Teva's subcutaneous depot is built to avoid the post-injection sedation that hobbled the first olanzapine shot. It cleared the FDA on 8 October; in the phase 3 SOLARIS trial it beat placebo on symptoms at eight weeks.
Abilify MyCite embeds a sensor in an antipsychotic tablet to log each dose to an app. Nearly a decade on, its own FDA label still says it has not been shown to improve whether patients take their medicine.
Cobenfy, approved in the US in September 2024, cut symptom scores more than placebo in two five-week trials — without the weight gain and movement effects of older drugs, but with cholinergic side effects.
In 4,868 clozapine users followed to 2023, excess neutropenia risk concentrated in the first 18 weeks and converged with other antipsychotics by around two years.
The ODDESSI trial ran in 30 clusters across five NHS trusts in England. Time to relapse was unchanged; inpatient admission, re-referral and service-user ratings all moved in Open Dialogue's favour.
A 1.5-million-person records study reports lower mortality with GLP-1 drugs than with SGLT2 inhibitors, and the largest absolute gains in people with serious mental illness. The design cannot prove it.
A registry study spanning 4.9 million people separates where the most deaths occur from where the inequality is largest. Heart disease and lung disease give different answers.
Bristol Myers Squibb found 'irregularities' in how a small number of ADEPT-2 sites executed the study, excluded their patients, and is enrolling more. Alzheimer's-related psychosis still has no approved treatment.
A within-individual analysis of 505,474 people in Finland and Sweden found lower psychiatric hospitalisation on clozapine in every disorder studied except borderline personality disorder, with no excess mortality signal.
A 22-year US analysis links hotter months to more overdose deaths. A British Columbia case-control study finds antipsychotic dispensing associated with dying in the 2021 heat dome.
In 270 patients whose voices persisted despite antipsychotics, the therapy beat matched clinical contact on hallucination severity by 2.26 points — significant, with a Cohen's d of 0.27.